152 related articles for article (PubMed ID: 37917176)
1. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
Suzuki T; Michihata N; Hashimoto Y; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2024 Jan; 183(1):415-424. PubMed ID: 37917176
[TBL] [Abstract][Full Text] [Related]
2. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
Michihata N; Suzuki T; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
[TBL] [Abstract][Full Text] [Related]
3. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
[TBL] [Abstract][Full Text] [Related]
5. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H
JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
10. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
Michihata N; Matsui H; Fushimi K; Yasunaga H
Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
[TBL] [Abstract][Full Text] [Related]
12. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
13. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
Suzuki T; Michihata N; Aso S; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
15. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
16. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
Chiang MH; Liu HE; Wang JL
Arch Dis Child; 2021 Jul; 106(7):662-668. PubMed ID: 33172886
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
J Am Heart Assoc; 2020 Sep; 9(17):e015308. PubMed ID: 32811256
[TBL] [Abstract][Full Text] [Related]
19. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
Wu Y; Hu L; Xie X; Li W; Wang Y; Zhang L; Huang P; Li F; Li J; Xia S; Yuan J; Li M; Wang Z; Zhang X
Am Heart J; 2024 Jul; 273():1-9. PubMed ID: 38508571
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
